<DOC>
	<DOC>NCT01488708</DOC>
	<brief_summary>The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399 in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).</brief_summary>
	<brief_title>On Open-Label Study in Participants With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Have completed 52 weeks of treatment in core studies (NCT01196091) (NCT01205438) Given written informed consent Test negative for pregnancy at the time of enrollment Agree to use a reliable method of birth control Unwilling to comply with study procedures Any condition that renders the participants unable to understand the nature and scope and possible consequences of the study Any condition that in the opinion of the investigator poses an unacceptable risk to the participants if study drug would be administered</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Immune System Disease</keyword>
</DOC>